

## Maya Skubatch

PARTNER

Patents and  
Innovations

Palo Alto  
SOMA

mskubatch@wsgr.com  
650-849-3330

### FOCUS AREAS

Biotech  
Clean Energy  
FoodTech and AgTech  
Global Generics  
Intellectual Property  
Israel  
Life Sciences  
Medical Devices  
Patents and Innovations

### HIGHLIGHTS

- Strategic Patent Counselor**  
Maya provides a holistic IP strategy to healthcare and other technology-driven companies.
- Comprehensive Deal Expertise**  
Maya assists clients with IP matters pertaining to financings, M&A, and partnership deals.

### EXPERIENCE

Maya Skubatch is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati and a former member of the firm's board of directors. Maya focuses on strategic patent counseling for life science companies. She represents both private and public companies and works closely with licensing, litigation, corporate, and regulatory counsel to provide her clients with a holistic IP strategy. Her strategic counseling includes developing a comprehensive IP strategy for early-stage companies that maximizes patent protection for their lead products in light of their product development timelines and positioning them for successful exits. Maya assists clients with IP matters pertaining to financings, M&A, and partnership deals. She also helps companies and investors in IP due diligence.

### CREDENTIALS

#### Education

- J.D., Santa Clara University School of Law  
*Intern, Affymetrix, Inc.; Extern in the chambers of the Honorable Judge Susan Illston, U.S. District Court, Northern District of California*
- B.A., Molecular and Cell Biology, University of California, Berkeley  
*Conducted research in the laboratories of Howard Hughes Professor Randy Scheckman and Professor Sung-Ho Kim*

#### Admissions

- State Bar of California
- Supreme Court of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Eastern District of California
- U.S. District Court for the Northern District of California
- U.S. District Court for the Southern District of California
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office

### MATTERS

## Select Representations

- Advised synthetic biology platform Hexagon Bio on intellectual property matters through its \$61 million Series B financing
- Representing Thorne Research in *inter partes* review (IPR Re: US 8,383,086 and IPR Re: US 8,197,807) against Dartmouth College, which has licensed the patent's rights to ChromaDex, Inc.
- Represented Day One Biopharmaceuticals in intellectual property matters related to its 2021 IPO
- Represented Progenity in *inter partes* review against Natera in connection with infringement claims of six patents related to prenatal genetic testing
- Developed IP for OneDraw™, a blood draw device that received FDA approval in 2019
- Developed IP for fremanezumab (Ajovy™), a Teva monoclonal antibody for the treatment of migraines
- Developed IP for deoxycholic acid (Kybella™), an Allergan product and the first FDA approved injectable for the treatment to reduce fat under the chin
- Carmenta through its acquisition by Progenity
- Etubics through its \$17M investment by NantCell
- Unity Biotechnology in intellectual property matters through its \$116M series B financing
- Drawbridge Health in its spinout from GE
- Mirna Therapeutics in intellectual property matters related to its 2015 IPO
- Labrys Biologics in intellectual property matters leading to its \$825 million acquisition by Teva
- Adverum in intellectual property matters related to its 2014 IPO and various follow-on offerings
- Verinata in intellectual property matters leading to its \$425 million acquisition by Illumina
- Ion Torrent in intellectual property matters leading to its \$725 million acquisition by Life Technologies
- Virdia in intellectual property matters leading to its \$62 million acquisition by Stora Enso
- Capp Medical in intellectual property matters leading to its acquisition by Roche

## INSIGHTS

---

### Select Publications

- Co-author with D. Hoffmeister, C. Andres, D. Van Goor, and I. Dasgupta, "Dietary Supplements And FDA: Potential For Partnership?" *Law360*, March 7, 2018
- Co-author with D. Hoffmeister, V. Norviel, and C. Andres, "Complying with Expanded Access Policy Drug Laws," *Law360*, February 28, 2017
- Co-author, Brief for *amici curiae* Amarantus Bioscience Holdings, Inc., Exo Incubator, Inc., and Michael Heltzen in support of petitioner, *Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al.*, On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief for *amici curiae* Population Diagnostics, Inc., Avant Diagnostics, Inc., Personalis, Inc., Linda Bruzzone, and Erin Marie Mading in support of petitioner, *Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al.*, On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief of *Amici Curiae* Amarantus Bioscience Holdings, Inc., Personalis, Inc., and Population Diagnostics, Inc. in Support of Appellants' Petition for Rehearing En Banc, *Ariosa Diagnostics, Inc. v. Sequenom, Inc.*, On Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 2014-1139, -1144
- Co-author, "A Novel Receptor for APO2L/Trail Contains a Truncated Death Domain," *Current Biology*, December 1, 1997
- Co-author, "TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," *Science* 277, August 8, 1997
- Co-author, "Herpevirus Entry Mediator: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family Interacts with Members of the Factors NF-kB and AP," *Journal of Biological Chemistry*, Vol. 296, May 30, 1997